دورية أكاديمية
أعرض في EDS

Preoperative serum CA125 level is a good prognostic predictor in patients with intrahepatic cholangiocarcinoma after hepatectomy: A single-center retrospective study.

التفاصيل البيبلوغرافية
العنوان: Preoperative serum CA125 level is a good prognostic predictor in patients with intrahepatic cholangiocarcinoma after hepatectomy: A single-center retrospective study.
المؤلفون: Meng J; Department of Health Management Center, The Affiliated Hospital of Guilin Medical University, Guilin, China., Weng J; Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Guilin Medical University, Guilin, China., Wu J; Department of Hepatic Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China., Mao H; Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Guilin Medical University, Guilin, China., Huang P; Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Guilin Medical University, Guilin, China., Chen S; Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Guilin Medical University, Guilin, China., Liu L; Department of Hepatobiliary and Pancreatic Surgery, Laboratory of Hepatobiliary and Pancreatic Surgery, Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair, The Affiliated Hospital of Guilin Medical University, Guilin, China.
المصدر: Medicine [Medicine (Baltimore)] 2023 Sep 08; Vol. 102 (36), pp. e34839.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Cholangiocarcinoma*/surgery , Bile Duct Neoplasms*/surgery, Humans ; Prognosis ; Hepatectomy ; Retrospective Studies ; Carcinoembryonic Antigen ; Margins of Excision ; CA-125 Antigen ; Bile Ducts, Intrahepatic ; Carbohydrates
مستخلص: Serum carbohydrate antigen 125 (CA125) is associated with the prognosis of various malignancies, including ovarian and pancreatic cancer. The relationship between preoperative serum CA125 level and the survival of patients with intrahepatic cholangiocarcinoma (ICC) has not been fully studied. The aim of this study was to explore the prognostic value of CA125 in ICC after hepatectomy. We retrospectively reviewed the clinicopathological data of 178 ICC patients who underwent hepatic resection. Receiver operating characteristic analyses were performed to estimate the relationships of serum CA125, α-fetoprotein, carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 with the prognosis of ICC. The predictive value of CA125 for the prognosis of ICC patients was demonstrated by univariate analyses and Cox proportional hazards models. CA125 was correlated with tumor size, differentiation, capsulation, tumor node-metastasis stage, recurrence, and CEA. Univariate analysis indicated that CA125, sex, tumor number, tumor size, differentiation, surgical resection margin, tumor node metastasis stage, and CEA were risk factors for both the overall survival and the disease-free survival of ICC patients. Cox proportional hazards models showed that preoperative elevated CA125, a tumor size > 5 cm, and an R1 surgical resection margin were independent prognostic predictors of overall survival and disease-free survival. CA125 also had strong predictive value for the prognosis of different ICC subgroups, including patients without lymph node metastasis and with elevated carbohydrate antigen 19-9 levels. Preoperative elevated serum CA125 level is a noninvasive, simple, and reliable indicator of the prognosis of ICC patients after hepatectomy.
Competing Interests: The authors have no funding and conflicts of interest to disclose.
(Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.)
References: Int J Cancer. 2002 Apr 10;98(5):737-40. (PMID: 11920644)
Int J Biol Macromol. 2023 Jan 15;225:809-821. (PMID: 36400211)
Pathobiology. 2012;79(2):101-6. (PMID: 22286058)
BMC Cancer. 2014 Jan 21;14:35. (PMID: 24447304)
Chin Clin Oncol. 2018 Oct;7(5):52. (PMID: 30180751)
Diagn Pathol. 2021 Apr 8;16(1):28. (PMID: 33832498)
J Gynecol Oncol. 2021 Sep;32(5):e72. (PMID: 34132070)
Nat Rev Cancer. 2009 Dec;9(12):874-85. (PMID: 19935676)
J Hepatol. 2008 Aug;49(2):207-16. (PMID: 18490072)
Hepatology. 2019 Apr;69(4):1803-1815. (PMID: 30251463)
Cancer Lett. 2023 Jan 28;553:215980. (PMID: 36336149)
World J Surg Oncol. 2023 Jan 20;21(1):16. (PMID: 36658564)
J Hepatol. 2020 Feb;72(2):364-377. (PMID: 31954498)
Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188503. (PMID: 33421585)
Surg Clin North Am. 2020 Jun;100(3):535-549. (PMID: 32402299)
Genomics Inform. 2013 Dec;11(4):239-44. (PMID: 24465236)
Hum Pathol. 2012 Oct;43(10):1755-63. (PMID: 22542127)
Mol Ther. 2021 Apr 7;29(4):1557-1571. (PMID: 33359791)
Carcinogenesis. 2021 Apr 17;42(3):327-343. (PMID: 33608706)
J Am Coll Surg. 2001 Oct;193(4):384-91. (PMID: 11584966)
Med Oncol. 2020 Nov 16;37(12):114. (PMID: 33196934)
Sci Transl Med. 2019 Jun 19;11(497):. (PMID: 31217340)
Clin Chim Acta. 2022 Jan 1;524:43-50. (PMID: 34813778)
Ann Surg Oncol. 2008 Feb;15(2):583-9. (PMID: 17955299)
Lancet. 2021 Jan 30;397(10272):428-444. (PMID: 33516341)
Nat Rev Dis Primers. 2021 Sep 9;7(1):65. (PMID: 34504109)
Cancer Sci. 2012 Apr;103(4):739-46. (PMID: 22320398)
المشرفين على المادة: 0 (Carcinoembryonic Antigen)
0 (CA-125 Antigen)
0 (Carbohydrates)
تواريخ الأحداث: Date Created: 20230908 Date Completed: 20230911 Latest Revision: 20230911
رمز التحديث: 20230911
مُعرف محوري في PubMed: PMC10489453
DOI: 10.1097/MD.0000000000034839
PMID: 37682202
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-5964
DOI:10.1097/MD.0000000000034839